Identification of the minimal region of peptide derived from ADP-ribosylation factor1 (ARF1) that inhibits IgE-mediated mast cell activation

Ryota Uchida, Tomonori Egawa, Yoshio Fujita, Kazuyuki Furuta, Hiroaki Taguchi, Satoshi Tanaka, Keigo Nishida

Research output: Contribution to journalArticle

Abstract

Mast cells play a pivotal role in allergic reactions and inflammations. Aggregation of the high affinity IgE receptor (FcεRI) eventually leads to the release of granule components such as histamine, as well as the de novo synthesis of inflammatory cytokines and lipid mediators. These substances are involved in the development of allergy and inflammation. Therefore, efficient inhibitors of mast cell activation would be therapeutically beneficial. We previously demonstrated that the synthetic peptide derived from the NH2-terminal region (2–17: GNIFANLFKGLFGKKE) of a small GTPase ARF1 (ADP-ribosylation factor1) inhibited FcεRI-induced mast cell degranulation. However, detailed structure-activity relationship study of NH2-terminal portion of ARF1 peptide has not been done. In addition, it is still unclear whether the NH2-terminal peptide of ARF1 suppresses FcεRI-induced production of cytokines and lipid mediators such as leukotriene C4 (LTC4) from mast cells. Here we show that amino acid residues K10-K16 are necessary for ARF1 peptide to efficiently inhibit FcεRI-induced activation of bone marrow-derived mast cells (BMMCs), indicated by decreased mast cell degranulation, cytokine secretion and leukotriene release. Furthermore, we show that ARF1 peptide inhibits IgE-mediated passive cutaneous anaphylaxis reaction. Our results suggest that the peptide derived from ARF1 could be developed into a novel anti-allergic agent for therapeutic intervention in allergy and mast cell-related pathologies.

Original languageEnglish
Pages (from-to)32-37
Number of pages6
JournalMolecular Immunology
Volume105
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Mast Cells
Adenosine Diphosphate
Immunoglobulin E
Peptides
Cell Degranulation
Hypersensitivity
Cytokines
Inflammation
Lipids
IgE Receptors
Leukotriene C4
Anti-Allergic Agents
Passive Cutaneous Anaphylaxis
Monomeric GTP-Binding Proteins
Leukotrienes
Structure-Activity Relationship
Histamine
Bone Marrow
Pathology
Amino Acids

Keywords

  • ARF1
  • Cytokine
  • Degranulation
  • Lipid mediator
  • Mast cells
  • Peptide

ASJC Scopus subject areas

  • Immunology
  • Molecular Biology

Cite this

Identification of the minimal region of peptide derived from ADP-ribosylation factor1 (ARF1) that inhibits IgE-mediated mast cell activation. / Uchida, Ryota; Egawa, Tomonori; Fujita, Yoshio; Furuta, Kazuyuki; Taguchi, Hiroaki; Tanaka, Satoshi; Nishida, Keigo.

In: Molecular Immunology, Vol. 105, 01.01.2019, p. 32-37.

Research output: Contribution to journalArticle

Uchida, Ryota ; Egawa, Tomonori ; Fujita, Yoshio ; Furuta, Kazuyuki ; Taguchi, Hiroaki ; Tanaka, Satoshi ; Nishida, Keigo. / Identification of the minimal region of peptide derived from ADP-ribosylation factor1 (ARF1) that inhibits IgE-mediated mast cell activation. In: Molecular Immunology. 2019 ; Vol. 105. pp. 32-37.
@article{c84f15f02a3447f8ad39c6f31f2fd0de,
title = "Identification of the minimal region of peptide derived from ADP-ribosylation factor1 (ARF1) that inhibits IgE-mediated mast cell activation",
abstract = "Mast cells play a pivotal role in allergic reactions and inflammations. Aggregation of the high affinity IgE receptor (FcεRI) eventually leads to the release of granule components such as histamine, as well as the de novo synthesis of inflammatory cytokines and lipid mediators. These substances are involved in the development of allergy and inflammation. Therefore, efficient inhibitors of mast cell activation would be therapeutically beneficial. We previously demonstrated that the synthetic peptide derived from the NH2-terminal region (2–17: GNIFANLFKGLFGKKE) of a small GTPase ARF1 (ADP-ribosylation factor1) inhibited FcεRI-induced mast cell degranulation. However, detailed structure-activity relationship study of NH2-terminal portion of ARF1 peptide has not been done. In addition, it is still unclear whether the NH2-terminal peptide of ARF1 suppresses FcεRI-induced production of cytokines and lipid mediators such as leukotriene C4 (LTC4) from mast cells. Here we show that amino acid residues K10-K16 are necessary for ARF1 peptide to efficiently inhibit FcεRI-induced activation of bone marrow-derived mast cells (BMMCs), indicated by decreased mast cell degranulation, cytokine secretion and leukotriene release. Furthermore, we show that ARF1 peptide inhibits IgE-mediated passive cutaneous anaphylaxis reaction. Our results suggest that the peptide derived from ARF1 could be developed into a novel anti-allergic agent for therapeutic intervention in allergy and mast cell-related pathologies.",
keywords = "ARF1, Cytokine, Degranulation, Lipid mediator, Mast cells, Peptide",
author = "Ryota Uchida and Tomonori Egawa and Yoshio Fujita and Kazuyuki Furuta and Hiroaki Taguchi and Satoshi Tanaka and Keigo Nishida",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.molimm.2018.11.002",
language = "English",
volume = "105",
pages = "32--37",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Identification of the minimal region of peptide derived from ADP-ribosylation factor1 (ARF1) that inhibits IgE-mediated mast cell activation

AU - Uchida, Ryota

AU - Egawa, Tomonori

AU - Fujita, Yoshio

AU - Furuta, Kazuyuki

AU - Taguchi, Hiroaki

AU - Tanaka, Satoshi

AU - Nishida, Keigo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mast cells play a pivotal role in allergic reactions and inflammations. Aggregation of the high affinity IgE receptor (FcεRI) eventually leads to the release of granule components such as histamine, as well as the de novo synthesis of inflammatory cytokines and lipid mediators. These substances are involved in the development of allergy and inflammation. Therefore, efficient inhibitors of mast cell activation would be therapeutically beneficial. We previously demonstrated that the synthetic peptide derived from the NH2-terminal region (2–17: GNIFANLFKGLFGKKE) of a small GTPase ARF1 (ADP-ribosylation factor1) inhibited FcεRI-induced mast cell degranulation. However, detailed structure-activity relationship study of NH2-terminal portion of ARF1 peptide has not been done. In addition, it is still unclear whether the NH2-terminal peptide of ARF1 suppresses FcεRI-induced production of cytokines and lipid mediators such as leukotriene C4 (LTC4) from mast cells. Here we show that amino acid residues K10-K16 are necessary for ARF1 peptide to efficiently inhibit FcεRI-induced activation of bone marrow-derived mast cells (BMMCs), indicated by decreased mast cell degranulation, cytokine secretion and leukotriene release. Furthermore, we show that ARF1 peptide inhibits IgE-mediated passive cutaneous anaphylaxis reaction. Our results suggest that the peptide derived from ARF1 could be developed into a novel anti-allergic agent for therapeutic intervention in allergy and mast cell-related pathologies.

AB - Mast cells play a pivotal role in allergic reactions and inflammations. Aggregation of the high affinity IgE receptor (FcεRI) eventually leads to the release of granule components such as histamine, as well as the de novo synthesis of inflammatory cytokines and lipid mediators. These substances are involved in the development of allergy and inflammation. Therefore, efficient inhibitors of mast cell activation would be therapeutically beneficial. We previously demonstrated that the synthetic peptide derived from the NH2-terminal region (2–17: GNIFANLFKGLFGKKE) of a small GTPase ARF1 (ADP-ribosylation factor1) inhibited FcεRI-induced mast cell degranulation. However, detailed structure-activity relationship study of NH2-terminal portion of ARF1 peptide has not been done. In addition, it is still unclear whether the NH2-terminal peptide of ARF1 suppresses FcεRI-induced production of cytokines and lipid mediators such as leukotriene C4 (LTC4) from mast cells. Here we show that amino acid residues K10-K16 are necessary for ARF1 peptide to efficiently inhibit FcεRI-induced activation of bone marrow-derived mast cells (BMMCs), indicated by decreased mast cell degranulation, cytokine secretion and leukotriene release. Furthermore, we show that ARF1 peptide inhibits IgE-mediated passive cutaneous anaphylaxis reaction. Our results suggest that the peptide derived from ARF1 could be developed into a novel anti-allergic agent for therapeutic intervention in allergy and mast cell-related pathologies.

KW - ARF1

KW - Cytokine

KW - Degranulation

KW - Lipid mediator

KW - Mast cells

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=85056872983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056872983&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2018.11.002

DO - 10.1016/j.molimm.2018.11.002

M3 - Article

C2 - 30472514

AN - SCOPUS:85056872983

VL - 105

SP - 32

EP - 37

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

ER -